OTCM
LNFIF
Market cap1mUSD
, Last price
USD
Name
Ellen AB
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
39.18%
Rev. gr., 5y
1.31%
Revenues
23m
-11.69%
Net income
-1m
L-59.19%
CFO
1m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ellen AB (publ) is a Swedish biotechnology firm specializing in the development and marketing of self-care products for women's intimate health. Its diverse product portfolio includes the ellen Probiotic Tampon, which combines sanitary protection with the delivery of beneficial lactic acid bacteria to support vaginal flora. Another key offering is the ellen Probiotic Intimate Crème, a hydrating cream designed to act as a protective barrier for delicate intimate skin and mucous membranes. For personal health monitoring, the company provides ellen pH-Control, a medical device enabling convenient at-home measurement of vaginal pH levels. Additionally, Ellen AB offers the ellen Sport Tampong/Aqua Block, engineered to prevent chlorinated or contaminated water from entering the vagina during swimming and other water-based activities. Under the LN brand, the company also presents a range of intimate hygiene solutions: LN Intimate Cleansing Foam, which cleanses and doubles as a shaving cream for intimate grooming; LN Intimate Deo, a softening deodorant formulated with lactic acid to foster a healthy vaginal environment; and LN After Shave & Wax Gel, developed to soothe skin after hair removal in intimate or other body areas. Ellen AB's products are distributed across several European markets, including France, Belgium, Germany, Switzerland, Austria, and Scandinavia. The company utilizes a network of distributors and retailers for sales, complemented by online sales specifically targeting the Scandinavian region. Founded in 2000, Ellen AB (publ) is headquartered in Stockholm, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||